| | |

Using Electric Fields to Treat Tumors: Combining Standard and Innovative Treatments

Using Electric Fields to Treat Tumors: Standard and Innovative TreatmentsMesothelioma is a rare cancer and standard therapies are limited. So most patients consider one or more different treatments. Different types of therapies can be used and they are usually not exclusive. Mesothelioma patients can move from one type to another. And, if their doctors agree, can sometimes use them in combination.

One of the non-standard treatment therapies is the use of electric fields. Tumor-treating electric fields can disrupt cancer cell division. This treatment is approved for mesothelioma treatment. A new combination of treatments has recently been proposed. Does the combination of tumor-treating fields with a standard treatment effective?

A new global clinical trial combined tumor-treating fields with sorafenib. This medication blocks cell protein signals to prevent cancer cells from multiplying.

Together, these two treatments block tumor cell growth in several ways. Research is promising that this treatment combination is effective.

A New Combination of Treatment Therapies

The combination of tumor-treating electric fields with sorafenib is not new. Laboratory research and clinical data from other cancer types were promising.

Twenty-seven patients were included in a new study published in Cancers. Each patient had large tumors and advanced disease.

Results showed that tumor-treating fields with sorafenib reduced the tumor size. This combination worked for 9.5% of patients. Sorafenib alone resulted in 4.5% of patients with reduced tumor size.

The reduction of tumor size was even better in patients who had both treatments for 12 weeks. A full 18% of patients showed a reduction in tumor size.

Oncologists are excited to begin a larger clinical trial to examine this combination. There were no new safety concerns or related toxicity in these patients.

Tumor-Treating Electric Fields Explained

Tumor-treating electric fields therapy is non-invasive. It works by selectively disrupting the division of cancer cells. It delivers low-intensity, intermediate frequency, alternating electric fields to the tumor.

Tumor-treating electric fields therapy is generated by a portable, wearable medical device. It may cause skin irritation in some patients. But this can be controlled using topical creams in most cases. It slows tumor growth and induces cancer cell death. They also help with DNA repair and immunological responses.

The multi-modal treatment of tumor-treating fields with sorafenib suggests new possibilities. There is broad applicability for this combination. And there are other combinations to try with other treatment options and modalities.

A New Treatment Option for Mesothelioma Patients

Tumor-treating electric fields (150 kHz) therapy with sorafenib resulted in patient improvements. The response rates were a ~2-fold increase versus sorafenib alone in adult patients. There were no new safety signals or concerns.

Furthermore, the response rate improved in patients who received 12 weeks of treatment. clinical data suggest that tumor-treating electric fields with sorafenib works.

This is a feasible and tolerable therapeutic option for some patients. This treatment combination deserves further investigation in a larger clinical study.

Source

Gkika, Eleni, Anca-Ligia Grosu, Teresa Macarulla Mercade, Antonio Cubillo Gracián, Thomas B. Brunner, Michael Schultheiß, Monika Pazgan-Simon, Thomas Seufferlein, and Yann Touchefeu. “Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.” Cancers 14, no. 6 (2022): 1568. https://doi.org/10.3390/cancers14061568

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…